A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

880

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Rilvegostomig
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Nab-paclitaxel

Sponsor

AstraZeneca